Full Press Release Details
I am text block. Click edit button to change this text. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
PVLA Neutral Sentiment
Schönfeld, D., Matschiner, G., Chatwel,l L., Trentmann, S., Gille, H., Hülsmeyer, M., Brown, N., Kaye, P.M., Schlehuber, S., Hohlbaum, A.M., Skerra, A. (2009) An engineered lipocalin specific for CTLA-4 reveals a combining site with structural and conformational features similar to antibodies. PNAS 19;106(20):8198-203.
Key Takeaway: The article presents a study on an engineered lipocalin specific for CTLA-4, highlighting its structural and conformational similarities to antibodies. The research was published in PNAS and contributes to understanding CTLA-4 interactions. However, the article lacks specific details or implications of the findings.
Price reaction · baseline $22.05 (2025-06-20 close) · hit pre-market · 2 other PVLA headline(s) in the window, move may be shared
day 0 close · peak
+2.2%
Market Sentiment Analysis
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+106%
120-day peak, hindsight
Typical move
8.9%
average across 5 past catalysts
Cash runway
~58 mo
Minimal dilution risk
Lead asset
PTX-022
Phase 3 · Pachyonychia Congenita